XPO5 and plasma cell myeloma: These results are along the lines of previous findings in non-small-cell lung cancer [27], colorectal cancer [42], and multiple myeloma [29] where the XPO5 AC genotype was associated with better prognosis (AC+CC genotype) in NSCLC and multiple myeloma and better treatment response (AC+AA genotype) in colorectal cancer.